These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30926878)

  • 1. The anti-cancer drugs curaxins target spatial genome organization.
    Kantidze OL; Luzhin AV; Nizovtseva EV; Safina A; Valieva ME; Golov AK; Velichko AK; Lyubitelev AV; Feofanov AV; Gurova KV; Studitsky VM; Razin SV
    Nat Commun; 2019 Mar; 10(1):1441. PubMed ID: 30926878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins.
    Chang HW; Valieva ME; Safina A; Chereji RV; Wang J; Kulaeva OI; Morozov AV; Kirpichnikov MP; Feofanov AV; Gurova KV; Studitsky VM
    Sci Adv; 2018 Nov; 4(11):eaav2131. PubMed ID: 30417101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curaxin-Induced DNA Topology Alterations Trigger the Distinct Binding Response of CTCF and FACT at the Single-Molecule Level.
    Lu K; Liu C; Liu Y; Luo A; Chen J; Lei Z; Kong J; Xiao X; Zhang S; Wang YZ; Ma L; Dou SX; Wang PY; Li M; Li G; Li W; Chen P
    Biochemistry; 2021 Feb; 60(7):494-499. PubMed ID: 33570402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.
    Gasparian AV; Burkhart CA; Purmal AA; Brodsky L; Pal M; Saranadasa M; Bosykh DA; Commane M; Guryanova OA; Pal S; Safina A; Sviridov S; Koman IE; Veith J; Komar AA; Gudkov AV; Gurova KV
    Sci Transl Med; 2011 Aug; 3(95):95ra74. PubMed ID: 21832239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BET inhibition disrupts transcription but retains enhancer-promoter contact.
    Crump NT; Ballabio E; Godfrey L; Thorne R; Repapi E; Kerry J; Tapia M; Hua P; Lagerholm C; Filippakopoulos P; Davies JOJ; Milne TA
    Nat Commun; 2021 Jan; 12(1):223. PubMed ID: 33431820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional Dysregulation of MYC Reveals Common Enhancer-Docking Mechanism.
    Schuijers J; Manteiga JC; Weintraub AS; Day DS; Zamudio AV; Hnisz D; Lee TI; Young RA
    Cell Rep; 2018 Apr; 23(2):349-360. PubMed ID: 29641996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism of directional CTCF recognition of a diverse range of genomic sites.
    Yin M; Wang J; Wang M; Li X; Zhang M; Wu Q; Wang Y
    Cell Res; 2017 Nov; 27(11):1365-1377. PubMed ID: 29076501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative characterization of G-Quadruplexes in the three-dimensional chromatin structure.
    Hou Y; Li F; Zhang R; Li S; Liu H; Qin ZS; Sun X
    Epigenetics; 2019 Sep; 14(9):894-911. PubMed ID: 31177910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs.
    Nesher E; Safina A; Aljahdali I; Portwood S; Wang ES; Koman I; Wang J; Gurova KV
    Cancer Res; 2018 Mar; 78(6):1431-1443. PubMed ID: 29339544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTCF: a Swiss-army knife for genome organization and transcription regulation.
    Braccioli L; de Wit E
    Essays Biochem; 2019 Apr; 63(1):157-165. PubMed ID: 30940740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YY1 Is a Structural Regulator of Enhancer-Promoter Loops.
    Weintraub AS; Li CH; Zamudio AV; Sigova AA; Hannett NM; Day DS; Abraham BJ; Cohen MA; Nabet B; Buckley DL; Guo YE; Hnisz D; Jaenisch R; Bradner JE; Gray NS; Young RA
    Cell; 2017 Dec; 171(7):1573-1588.e28. PubMed ID: 29224777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide DNA methylation reprogramming in response to inorganic arsenic links inhibition of CTCF binding, DNMT expression and cellular transformation.
    Rea M; Eckstein M; Eleazer R; Smith C; Fondufe-Mittendorf YN
    Sci Rep; 2017 Feb; 7():41474. PubMed ID: 28150704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional roles of CTCF in breast cancer.
    Oh S; Oh C; Yoo KH
    BMB Rep; 2017 Sep; 50(9):445-453. PubMed ID: 28648147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering essential cistromes using genome-wide CRISPR screens.
    Fei T; Li W; Peng J; Xiao T; Chen CH; Wu A; Huang J; Zang C; Liu XS; Brown M
    Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25186-25195. PubMed ID: 31727847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma.
    Zhang B; Zhang Y; Zou X; Chan AW; Zhang R; Lee TK; Liu H; Lau EY; Ho NP; Lai PB; Cheung YS; To KF; Wong HK; Choy KW; Keng VW; Chow LM; Chan KK; Cheng AS; Ko BC
    J Pathol; 2017 Dec; 243(4):418-430. PubMed ID: 28862757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of CTCF-associated chromatin neighborhood inhibits TAL1-driven oncogenic transcription program and leukemogenesis.
    Li Y; Liao Z; Luo H; Benyoucef A; Kang Y; Lai Q; Dovat S; Miller B; Chepelev I; Li Y; Zhao K; Brand M; Huang S
    Nucleic Acids Res; 2020 Apr; 48(6):3119-3133. PubMed ID: 32086528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The LDB1 Complex Co-opts CTCF for Erythroid Lineage-Specific Long-Range Enhancer Interactions.
    Lee J; Krivega I; Dale RK; Dean A
    Cell Rep; 2017 Jun; 19(12):2490-2502. PubMed ID: 28636938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTCF-Mediated Enhancer-Promoter Interaction Is a Critical Regulator of Cell-to-Cell Variation of Gene Expression.
    Ren G; Jin W; Cui K; Rodrigez J; Hu G; Zhang Z; Larson DR; Zhao K
    Mol Cell; 2017 Sep; 67(6):1049-1058.e6. PubMed ID: 28938092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 3D Genome as a Target for Anticancer Therapy.
    Kantidze OL; Gurova KV; Studitsky VM; Razin SV
    Trends Mol Med; 2020 Feb; 26(2):141-149. PubMed ID: 31679987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type.
    Lupey-Green LN; Caruso LB; Madzo J; Martin KA; Tan Y; Hulse M; Tempera I
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.